Corona vaccine hopeful BioNTech latches on to biopharma fever
BioNTech, the German biopharmaceuticals company, is selling 5.5m American Depositary Receipts (ADRs) on the Nasdaq through a share sale and a rights issue. The company, which is working with Pfizer to develop a vaccine for Covid-19, is the latest issuer to hit the market in a wave of biotech ECM issuance — but buyers are being warned against being too eager, reports Sam Kerr.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: